The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Comprehensive analysis of KRAS and NRAS mutations as predictive biomarkers for single agent panitumumab (pmab) response in a randomized, phase III metastatic colorectal cancer (mCRC) study (20020408).
Scott D. Patterson
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Marc Peeters
Consultant or Advisory Role - Amgen
Honoraria - Amgen
Research Funding - Amgen
Other Remuneration - Amgen
Salvatore Siena
Consultant or Advisory Role - Amgen; Bayer; Celgene; Genomic Health; Roche; Sanofi
Eric Van Cutsem
Research Funding - Amgen
Yves Humblet
Consultant or Advisory Role - Amgen
Honoraria - Amgen
Research Funding - Amgen
Jean-Luc Van Laethem
No relevant relationships to disclose
Thierry Andre
Consultant or Advisory Role - Amgen
Honoraria - Amgen
Ying Tian
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Roger Sidhu
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Kelly S. Oliner
Employment or Leadership Position - Amgen
Stock Ownership - Amgen